|
Oct 6
|
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
|
|
Oct 5
|
This Market-Beating Stock Just Gave Investors More Reasons to Invest
|
|
Oct 4
|
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
|
|
Oct 4
|
Shareholders in Intellia Therapeutics (NASDAQ:NTLA) have lost 51%, as stock drops 8.3% this past week
|
|
Oct 3
|
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
|
|
Oct 3
|
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
|
|
Aug 4
|
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
|